Volume 8 Supplement 1
Edited by Marcel Hommel
Publication of this supplement has been sponsored by Novartis Pharma AG.
This article gives an overview of some of the ongoing challenges that are faced in the prevention, diagnosis and treatment of malaria.
Artemisinin, from which the artemether component of Coartem®(artemether/lumefantrine, AL) is derived, is obtained from the plant sweet wormwood (Artemisia annua) which has been used for over 2,000 years as a Chin...
Artemether and lumefantrine (AL), the active constituents of Coartem® exhibit complementary pharmacokinetic profiles. Artemether is absorbed quickly; peak concentrations of artemether and its main active metaboli...
Current World Health Organization (WHO) guidelines for the treatment of uncomplicated falciparum malaria recommend the use of artemisinin-based combination therapy (ACT). Artemether/lumefantrine is an ACT preq...
This article reviews the comprehensive data on the safety and tolerability from over 6,300 patients who have taken artemether/lumefantrine (Coartem®) as part of Novartis-sponsored or independently-sponsored clini...
Infants and children under five years of age are the most vulnerable to malaria with over 1,700 deaths per day from malaria in this group. However, until recently, there were no WHO-endorsed paediatric anti-ma...
Malaria is one of the most significant causes of morbidity and mortality worldwide. Every year, nearly one million deaths result from malaria infection. Malaria can be controlled in endemic countries by using ...
Citation Impact
3.469 - 2-year Impact Factor (2021)
3.570 - 5-year Impact Factor (2021)
1.277 - Source Normalized Impact per Paper (SNIP)
1.307 - SCImago Journal Rank (SJR)
Speed
48 days to first decision for all manuscripts (Median)
59 days to first decision for reviewed manuscripts only (Median)
Usage
3,813,083 downloads (2021)
5,737 Altmetric mentions (2021)